Results 101 to 110 of about 5,587,857 (353)

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

open access: yesMolecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute   +4 more
wiley   +1 more source

The Christian movement in Japan.

open access: yes, 1906
"Missionary directory--1907": p. [343]-398.Title-page in Japanese at end.1913-1914: "Including Korea and Formosa."Mode of access: Internet.Imprint varies: 1906-1910, The Standing Committee of Cooperating Christian Missions (Japan); 1911-1914, The ...
Conference of Federated Missions (Japan)   +1 more
core  

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

open access: yesMolecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric   +10 more
wiley   +1 more source

Japan Update conference (2013- )

open access: yes, 2019
The Japan Update is the flagship conference of the Australia-Japan Research Centre (AJRC) in Crawford School of Public Policy, and the Japan Institute at The Australian National University.
Australian National University. Japan Institute
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Adapting Live-Action Role-Play in Japan --How German Roots Do Not Destine Japanese Routes [PDF]

open access: yes, 2019
[Replaying Japan 2019] 日時: 2019 年8月9日(金)-11日(日), 場所: 立命館大学衣笠キャンパス(創思館、存心館、以学館), 主催: 立命館大学ゲーム研究センターLive-action role-play (larp), a mixture of improv-theatre and role-playing game where participants interact physically as characters in a shared story ...
Björn-Ole, Kamm, Kamm, Björn-Ole
core  

continuum: Independent Animation from Japan and Australia

open access: yes, 2023
This exhibition celebrates 15 vibrant and subtly subversive works of contemporary independent animation from filmmakers across Australia and Japan. The works featured in the collection seek to stand apart from mainstream animation, offering viewers a ...
Yano, H, Szapiro, D
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Financial reform in Japan [PDF]

open access: yes
Japan ; Financial institutions ...
Charles Pigott
core  

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy